Who is sponsoring NCT03871556?

NCT03871556 is sponsored by Northwestern University.

What drugs are being tested in NCT03871556?

Interventions in NCT03871556: LOGIQ P6 Diagnostic Ultrasound.

What condition does NCT03871556 study?

NCT03871556 studies Subcutaneous Fat.

Is NCT03871556 still recruiting?

NCT03871556 is currently completed. Last updated 28 September 2023.

Are results published for NCT03871556?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-09-28 · How we verify

NCT03871556

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diagnostic Ultrasound for Measuring Fat of the Body

Completed NA Results posted Last updated 28 September 2023

What this trial tests

NA trial testing LOGIQ P6 Diagnostic Ultrasound in Subcutaneous Fat in 40 participants. Completed in 2 October 2022.

Timeline

20 March 2019

Primary endpoint
2 October 2022

2 October 2022

Quick facts

Lead sponsor	Northwestern University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	40
Start date	20 March 2019
Primary completion	2 October 2022
Estimated completion	2 October 2022
Sites	1 location across United States

Drugs / interventions tested

LOGIQ P6 Diagnostic Ultrasound

Conditions studied

Subcutaneous Fat — all drugs for Subcutaneous Fat →

Sponsor

Northwestern University

Who can join

Adults 18 to 85, any sex, with Subcutaneous Fat. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Difference in Thickness of Subcutaneous Fat at Different Anatomic Sites on the Body Primary · through study completion, 1 day

Will use diagnostic ultrasound to measure fat thickness

Chin

Group	Value	95% CI
Male	.56	± .27
Female	.60	± .14

Left arm

Group	Value	95% CI
Male	.83	± .59
Female	1.65	± .57

Right arm

Group	Value	95% CI
Male	.82	± .51
Female	1.72	± .58

Left back

Group	Value	95% CI
Male	.77	± .44
Female	1.30	± .45

Right back

Group	Value	95% CI
Male	.86	± .51
Female	1.20	± .52

Left flank

Group	Value	95% CI
Male	1.31	± .58
Female	1.81	± .47

Right flank

Group	Value	95% CI
Male	1.16	± .55
Female	1.83	± .47

Abdomen

Group	Value	95% CI
Male	1.71	± .70
Female	2.19	± .61

Gender Differences on Patient Perceptions of Body Image With Measured Fat Distribution Primary · through study completion, 1 day

Will use diagnostic ultrasound to measure fat thickness and a questionnaire to assess subject perceptions of their body using a 10-point Likert scale (1= very unsatisfied, 10= very satisfied)

Chin

Group	Value	95% CI
Male	8.48	± 1.38
Female	5.14	± 3.47

Inner arms

Group	Value	95% CI
Male	7.41	± 2.45
Female	4.02	± 3.22

Upper back

Group	Value	95% CI
Male	7.90	± 1.91
Female	5.18	± 2.81

Flanks

Group	Value	95% CI
Male	6.48	± 2.6
Female	3.45	± 2.97

Abdomen

Group	Value	95% CI
Male	5.98	± 2.71
Female	2.93	± 3.12

Inner thigh

Group	Value	95% CI
Male	7.58	± 2.12
Female	5.04	± 3.62

Outer thigh

Group	Value	95% CI
Male	7.91	± 2.25
Female	5.93	± 3.15

Overall

Group	Value	95% CI
Male	7.28	± 2.13
Female	4.70	± 2.24

Sponsor's own description

The purpose of this study is to provide information about human subcutaneous fat thickness at different anatomic sites on the body by measuring these thicknesses with a diagnostic ultrasound and also by correlating patient perceptions of body image with measured fat distribution. Subjects currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be considered for enrollment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Northwestern University trials

Trials by the same sponsor.

NCT06545695 — Epidermal Growth Factor Receptor Inhibition for Keratinopathies · Phase 1, PHASE2 · not yet recruiting
NCT07261657 — N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C · EARLY_PHASE1 · not yet recruiting
NCT07392775 — ALDH2 Genetic Testing in East Asian Community · NA · not yet recruiting
NCT06886776 — Implementing A Secure Firearm Storage Program in Illinois Health Centers in Partnership With AllianceChicago and the Ill · NA · not yet recruiting
NCT07469176 — Co-Designing and Evaluating Additional Mothers and Babies Program Content for Expectant and New Parents of Children With · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03871556 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Northwestern University
Last refreshed: 28 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03871556.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing